Biological Materials

Biological Materials. Means tangible biological materials that are necessary for the effective exercise of the Patent Rights, which materials are described on Exhibit A, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of isolated DNA or RNA, and... substances routinely purified from a source material included in the original materials (such as, recombinant proteins isolated from a cell extract or supernatant by non-proprietary affinity purification methods). Exhibit A shall be periodically amended to include any additional Biological Materials that Medical School may furnish to Company. View More

Biological Materials. The term "Biological Materials" shall mean any Technology in the form of tangible materials together with any progeny, mutants, or derivatives thereof developed in performance of the Research Program.

Biological Materials. Shall mean the biological materials set forth in Appendix B, and all Progeny and Unmodified Derivatives of those materials, but excluding Modifications. "Progeny" shall mean an unmodified descendant from the Biological Materials, such as virus from virus, cell from cell, or organism from organism. "Unmodified Derivatives" shall mean substances created by * CONFIDENTIAL TREATMENT REQUESTED Tepha which constitute an... unmodified functional subunit or product expressed by the Biological Material(s), (some examples include: subclones of unmodified cell lines, purified or fractionated subsets of the Biological Material(s), proteins expressed by DNA/RNA supplied by Metabolix, or monoclonal antibodies secreted by a hybridoma cell line). View More

Biological Materials. Shall mean the biological materials as specifically described in Exhibit B, as amended from time to time.

Biological Materials. Tangible biological materials that, to the extent that CSHL has a right to transfer such materials, are necessary for the effective exercise of the Patent Rights and are actually provided by Dr. Hannon or a member of Dr. Gregory Hannon's lab to the Company, as well as additional tangible materials that are routinely produced through use of those materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from... isolated DNA or RNA, recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials (such as, recombinant proteins isolated from a cell extract or supernatant by non-proprietary affinity purification methods). Dr. Hannon will secure the approval of CSHL and/or, as needed, the Howard Hughes Medical Institute (HHMI) prior to the transfer of any such Biological Material to Company. View More

Biological Materials. Any plant, seed, propagule, embryo, leaf, root and/or other plant part or tissue, and/or gene construct or fragment thereof, belonging to or produced for the Company and/or its Affiliates, including any of the foregoing produced by Employee or produced by others during Employee's employment with the Company.